Read Time: 3 mins

Optimising Epilepsy Therapy – Searching for the Evidence – Looking Beyond the Data

Copy Link
Published Online: Nov 4th 2015 European Neurological Review, 2015;10(2):164–70 DOI:
Authors: Mar Carreño, Eugen Trinka, Martin Holtkamp
Quick Links:
Article Information

There is now an extensive range of anti-epileptic drugs (AEDs) available including older established treatments and a newer generation of medications. The choice of drugs and what constitutes optimal therapy, however, is unclear due to limitations in the data supporting their use, particularly among the newer treatments. In clinical trials of monotherapy, a treatment is required to show only non-inferiority to another benchmark treatment. In trials of polytherapy, comparisons are limited to placebo. It is therefore necessary to look beyond the study data and consider other parameters to ascertain the most suitable treatment for the individual patient. Available evidence suggests that efficacy is similar among most AEDs, but this does not mean they are all the same. Some show efficacy in early and refractory epilepsy and some improve depression and quality of life (QOL) in epilepsy. AEDs are associated with a range of adverse events (AEs) that can limit their usefulness. AE classifications include type A (augmented and dose related) including tiredness, fatigue, insomnia, dizziness, vertigo, imbalance, ataxia, tremor and cognitive impairment; type B (bizarre and idiosyncratic) including various hypersensitivity reactions; type C (chronic long-term toxicity) including hirsutism, alopecia, weight gain and obesity; and type D (teratogenesis and carcinogenesis). The newer AEDs have been more thoroughly assessed for AEs than older drugs and risks are better understood. In AED safety, it is not better to follow a policy of ‘better the devil you know’ but rather to carefully monitor AE incidence and be prepared to switch drugs to improve tolerability and avoid non-compliance and treatment failure.


Anti-epileptic drugs, safety, tolerability, efficacy, monotherapy, polytherapy, clinical trials


Epilepsy is one of the most common serious neurological disorders and has far-reaching consequences, not only for patients living with the condition, but also for their families and society as a whole.1 It is useful therefore to evaluate whether the advent of newer anti-epileptic drugs (AEDs) has progressed the safety and tolerability of epilepsy therapy. These newer treatments have been designed to overcome some of the safety issues of older treatments that have a major impact on the quality of life (QoL) of people with epilepsy.2–5 The newer drugs have been more extensively evaluated in post-marketing surveillance, which has uncovered safety concerns that may not have been apparent during short-term clinical trials. Comparing the efficacy of available AEDs is difficult due to the absence of head-to-head trials.6 The effective management of epilepsy not only involves controlling seizures, but also other factors such as impact on comorbidities.7 Real-world studies are important in supporting the efficacy findings of randomised clinical trials, but they have limitations.8,9 This article reports a symposium on optimising epilepsy therapy that was convened at the first Congress of the European Academy of Neurology in Berlin in June 2015. The symposium aimed to provide practical advice that could be applied to current daily practice and focussed on how the appropriate AEDs should be chosen, the need to consider the personal circumstances and goals of individual patients during this process.

Efficacy of Old and New AEDs – Are They All the Same?

Martin Holtkamp

Treatment Concepts in Epilepsy
The overall aim of epilepsy treatment is to maintain a seizure-free state, enabling patients to lead a normal life with minimal adverse events (AEs) (Figure 1). A poll of the symposium audience found that 48.5 % considered efficacy and 48.5 % considered safety to be the most important factor in choosing an AED, indicating that both aspects are equally important. Treatments vary according to the type of epilepsy. A prospective trial found that 58 % of patients had partial, 23 % had generalised and 19 % had unclassified epilepsy.10 Drugs licensed as monotherapy for generalised or partial epilepsy and those that are licensed as add-on therapy for partial epilepsy are given in Table 1. This includes both old and new AEDs and raises the important question, in terms of efficacy, are they all the same?

Anti-epileptic Drug Monotherapy
The European Medicines Agency ruled that in regulatory clinical trials, new AEDs for monotherapy should be compared with an optimal current therapy and demonstrate non-inferiority rather than superiority. As an example, a Phase III comparison of controlledrelease carbamazepine (CBZ) (up to 600 mg/day) versus zonisamide (ZNS, up to 300 mg/day) (n=456), showed that 84 % and 79 % of patients, respectively, were seizure-free at 6 months and 75 % and 68 % at 12 months indicating similar efficacy.11 This study formed basis of the monotherapy approval of ZNS in Europe.

The UK Standard and New Antiepileptic Drugs (SANAD) study on patients with partial epilepsy compared the effectiveness of multiple AEDs: CBZ, gabapentin (GBP), lamotrigine (LTG), oxcarbazepine (OXC) and Topiramate (TPM) in one of two concurrent pragmatic parallel-group unblinded randomised trials (n=1,721).12 Over 12 months, in terms of time to treatment failure, LTG was significantly superior to CBZ and OXC, which were significantly superior to GBP and TPM. These differences in effectiveness were maintained over 6 years (log-rank test statistic=22.15, p<0.0001). In terms of tolerability, LTG and GBP were significantly superior to OXC, which was significantly superior to CBZ and TPM.12

Anti-epileptic Drug Polytherapy
In AED polytherapy studies, patients can receive a standard therapy to which additional doses of test therapy or placebo are added. An example was a Phase III comparison of eslicarbazepine acetate (ESL) (400, 800 or 1,200 mg OD with titration) with placebo in patients receiving one or two concomitant AEDs over a 12-week period.13 The 1,200 mg dose produced a significant increase in seizure-free patients versus placebo (8 versus 2 %, p<0.05) and both the 800 and 1,200 mg doses produced significant increases in responder rates (a reduction in seizure frequency >50 %) versus placebo (34 % 800mg and 43 % 1200mg versus placebo 20 % , p<0.05 and p<0.001).

In polytherapy trials, investigations of 12 different AEDs showed widely differing and limited responder rates compared with placebo (20–45 % versus 5–20 %),3,14,15 and it was not possible to conclude which treatment is most effective. This was due to variability in the study populations and a shortage of head-to-head comparative trials. This lack of clear difference was emphasised in a recent meta-analysis that

included data from 40 trials comparing one AED with placebo, two trials comparing two AEDs and one trial comparing two AEDs and placebo.16 The comparative risk ratios for seizure outcome were determined for eleven different AEDs versus placebo. Whilst there is an increasing trend in median efficacy from LCM to TPM, the 95 % credible intervals overlap to the extent that it is not possible to show significant differences in efficacy between the drugs.

A factor that strongly influences the efficacy of AEDs is the number of previous treatments a patient has received. A study on 478 consecutive patients showed seizure-free rates decreased from 62 % for patients who had received no previous AEDs to 0 % for those who had received seven previous AEDs.17In addition, responder rates decreased from 85 to 35 % between zero and seven previous treatments. All of these findings suggest that the methods in the regulatory trials used to license AEDs are deficient; they were not reflective of the real world of epilepsy and did not explore the complexities of polytherapy or treatment history. For approval, it is only necessary to know whether the drug is more effective than placebo.

The Retrospective Study of Lacosamide as Early Add-on Along One Year (REALLY) showed that in a group of patients who had one AED failure (n=89), the seizure-free rate was 58 % after 12 months compared with 34.3 % for patients who had two AED failures (n=110).18 Responder rates were 83.0 % and 70.4 % for the same groups. The Eslicarbazepine acetate in Partial Onset Seizures (EPOS) study,19 was a prospective, multicentre non-interventional trial of 219 patients who were not seizure-free with monotherapy and were given ESL as add-on therapy. Among the patients, 59 % had received two previous AEDs, 81 % had received three previous AEDs and 19 % had received more than three. After 6 months of treatment, 82 % of patients were retained on ESL (primary endpoint). The major reasons for discontinuation (n=31, 18 %) were an AE (n=22) and lack of efficacy (n=4). In terms of secondary endpoints, 26 % and 39 % of patients were seizure-free at 3 and 6 months, respectively, and 70 % and 82 % were responders at 3 and 6 months, respectively (Figure 2).19 The retention and responder rates for those receiving concomitant CBZ, levetiracetam (LEV), LTG, or valproic acid (VPA) in this study were not significantly different (75–100 % and 70–90 %).20 Although CBZ and ESL are drugs which belong to the same chemical family, this study showed no significant difference

between the combination ESL/CBZ and combinations of ESL and the other three drugs. This finding is supported by the Phase III study that compared ESL with placebo as add-on therapy.13 There was no significant difference in efficacy independently of the patients being concomitantly treated with CBZ or not.

In recent experimental studies, it was shown that in hippocampal slices from therapy refractory epilepsy patients, seizure-like activity was largely resistant to CBZ, whereas eslicarbazepine showed potent activity on sodium current recovery from inactivation and discharge behaviour. Moreover, eslicarbazepine displayed add-on effects when applied in addition to CBZ. This data shows that eslicarbazepine retains cellular efficacy in chronic human epilepsy, whereas efficacy of CBZ seems to be lost.

In AED polytherapy, the main determinant of QoL in epilepsy is depression, a comorbidity that occurs in up to 20 % of patients in large community care studies and almost 50 % of patients in tertiary care

centres.22 During a one-year open-label extension of the pivotal Phase III trial of ESL, overall Montgomery–Asberg Depression Rating Scale (MADRS) scores were significantly reduced by 2.0 points (p<0.0001) and Quality of Life in Epilepsy Inventory-31 (QOLIE-31) scores were significantly improved by 3.8 points (p<0.0001).23 This suggests that ESL has a beneficial effect on depressive symptoms and resultant QoL in addition to seizure control.

In epilepsy, therefore, treatment aims to provide excellent seizure control with minimal AEs. Clinical trials of AEDs do not, however, reflect the real world of epilepsy. The evaluation of AED monotherapy is limited since the design of regulatory clinical trials enables only non-inferiority but not superiority of new drugs to be shown. In trials of AED polytherapy, placebo is used in the comparator arm but interdrug comparisons are difficult due to the lack of head-to-head trials. The efficacy of AEDs may appear similar but the drugs, however, are not all the same. Evidence from recent studies shows that ESL is effective in patients with early and refractory epilepsy and may be useful in cases of pharmacoresistance to CBZ. Some of the AEDs such as CBZ, LTG and ESL have the added advantage in stabilising or improving depressive symptoms, which have the most detrimental effects on QoL in epilepsy.

Safety of Old and New AEDs – Better the Devil We Know?

Eugen Trinka

Physicians treating patients with epilepsy all have opinions of the efficacy and safety of the multiple AEDs that are available, but the choice of treatment is often based on personal perception rather than an overall assessment of the evidence.5 AEDs are divided into ‘old’ types that were introduced from the 1860s to 1980 (bromide to valproate) and the ‘new’ types that were introduced from 1980 to the present (vigabatrin [VGB] to perampanel [PER]). Although AEDs have been available for approximately 150 years, AEs are a substantial cause of treatment failure and seriously diminish the QoL of many patients receiving them. Patients do not tend to report AEs spontaneously, particularly those of sexual dysfunction, or mood disorders. For this reason, it is necessary to actively screen patients using questionnaires or surveys. In seven studies of epilepsy therapy that screened for AEs (n=100–809), AE rates of 27.3–42.7 % were recorded.24 The World Health Organisation classifies AEs with AEDs into five types (Types A–E)24,25 (Figure 3).

Type A AEs are augmented or dose-related; these are the most common type, occurring in over 10 % of patients. They can be attributed to known drug mechanisms, tend to occur at the beginning of treatment or after dose escalation, may abate over time and are predictable or reversible. Type A AEs include drowsiness, lethargy, tiredness, fatigue, insomnia, dizziness, unsteadiness, vertigo, imbalance, ataxia, diplopia, tremor and cognitive impairment. They tend to occur immediately after a medication dose during times of peak serum levels. In pharmacokinetic studies, doses of OXC were compared with ESL.26 ESL doses of 1200mg/day resulted in higher levels of S-licarbazepine, lower levels of the R-licarbazepine and lower levels of oxcarbazepine in both plasma and CSF. Doses of 1200mg/day of OXC, however, produced a transient but pronounced (2–4 hours) peak in oxcarbazepine levels and higher levels of R-licarbazepine, which are believed to correlate with the occurrence of AEs. These results indicate that altering the pharmacokinetics of AEDs can markedly reduce AE incidence. An alternative approach is to switch from immediate release- to modified-release medications, which also reduces the incidence of AEs.27

Type A AEs are also more likely to occur when an AED has not been titrated or has been titrated too rapidly. A pooled analysis of three phase III trials that included 1,238 patients with partial onset seizures showed that patients who were titrated from 400mg ESL up to 800mg or 1200mg reported fewer AE’s than those patients who received a starting dose of 800mg (Figure 4).

There are remarkably little data on the cognitive effects of new AEDs. Limited study evidence shows that LTG and LEV cause fewer cognitive effects than CBZ, which has similar effects to phenytoin (PHT).29–32 TPM appears to have the worst cognitive effect profile among these drugs and has produced greater effects in studies compared with LTG and GBP. PER has a similar effect on cognitive function to placebo. The new AEDs, therefore, are generally better tolerated than the older AEDs, but there are exceptions to this trend.

The incidence of AEs is also affected by baseline medications when another AED is added. A study of 1,308 patients with partial onset seizures received placebo or 200, 400 or 600 mg lacosamide (LCM).33 AE incidence was greater in those patients who had received a baseline sodium channel blocker compared with those who had received an alternative AED. The rates of these events also increased with greater dose levels of LCM. This effect was also seen in a study that included 797 patients with ≥4 partial-onset seizures per 4 weeks despite treatment with 1–3 AEDs.34 The safety results were stratified according to the doses of CBZ the patients received (0≤800 mg or >800 mg CBZ/day) at baseline prior to switching treatment to placebo or ESL 400, 800 or 1,200 mg/day. Among patients, the incidence of dizziness, diplopia and abnormal coordination was seen to generally increase with rising ESL dose, but this effect was also increased by prior CBZ dose.

Clinical study findings show that measures of QoL are affected to a greater extent by mood and central nervous system (CNS) AEs arising from AED exposure than by seizure frequency.35–37 Some AEDs such as ESL improve measures of QoL as was shown in a study (n=255). The overall Mean QOL in Epilepsy Inventory-31 (QOLIE-31) scores after 1 year of treatment were significantly improved over baseline scores (p<0.0001). In addition, most of the mean MADRS scores for depression AEs and QoL were significantly reduced during the same time interval.

To avoid or limit type A AEs, therefore, it is necessary to start at low doses, up-titrate slowly and target the lowest effective maintenance dose. If no improvement is seen in AEs, it is advisable to either reduce, discontinue the dose, or modify the dosing scheme (e.g. change from bid to tid). A better option may be to use a different formulation (e.g. change from immediate release to slow release CBZ).

AED type B AEs are bizarre or idiosyncratic. These are uncommon or rare (<1–<0.1 %) and are related to individual vulnerability such as genetic factors but not to dose. These events occur mostly in the first weeks but can occur after years and are unpredictable with high morbidity and mortality and may be irreversible.24,25,38–40 Type B events include skin rashes, severe mucocutaneous reactions, aplastic anaemia, agranulocytosis, hepatotoxic effects, pancreatitis, angle-closure glaucoma and aseptic meningitis. These idiosyncratic events are hard to predict in trials because they have an incidence of 1/10,000. In order to detect these events with a 95 % probability, a population of 30,000 patients would have to be exposed to the drug, which is impractical.24,41–43 As a result, open-label and observation studies are required in the post-marketing phase; these provide lower level evidence but are important aspects of monitoring drug safety.

Type B reactions also include hypersensitivity reactions such as antiepileptic drug hypersensitivity syndrome (AHS) and systemic symptoms (DRESS), both of which are associated with 10–20 % mortality. Other hypersensitivity reactions include fever, eosinophilia, arthralgia, organ involvement with skin alterations and drug reaction with eosinophilia. Whilst these reactions are rare (1–2/million/year), they can occur at much higher frequencies if a drug is not properly titrated as was the case with LTG in which reaction rates were as high as 1/200.44–46 Hypersensitivity reactions are also associated with age, genetic factors, patient history and radiotherapy and have a potential association with human herpes viruses 4, 6 and 7. Increased hypersensitivity reactions have also been associated with HLA*1502 positivity in a large population of Han Chinese (post-test probability of 26 %)47 and with HLA-A*3101 negativity among Europeans (post-test probability of 3.8 %).48 These tests only indicate marginally increased risks, and it is important to determine those patients who have a history of rash prior to treatment.

Both old and new AEDs can cause type B AEs. In a large cohort study of epilepsy patients who were treated with CBZ; LEV; phenobarbital (PB); PHT or VPA, blood dyscrasias occurred in 3–4/100,00049 (compared with 1–2/100,000 in the general population). VGB has been associated with visual field defects in 41 % of patients50 and TPM has been associated with acute angle closure glaucoma (0.66 % after 6 months, 7.41 relative risk in first month).51 In an estimated population of 605 patients who received retigabine, 38 (6.3 %) showed skin discolouration after a median 4.1 years, and 36 had eye examinations.34 Among these, 11/36 had retinal pigmentary abnormalities, 5 of whom had worse than 20/20 visual acuity and 1 developed retinal dystrophy. In summary, new AEDs may cause surprises in terms of type B AEs, and physicians should look out for them.

To limit the occurrence of type B events, therefore, certain AEDs should be avoided in high-risk groups or used with caution and uptitrate slowly. AEDs causing reactions should be promptly discontinued and symptomatic and supportive care (intravenous immunoglobulins, steroids, etc.) should be given. In addition, new observations should be reported to create new safety signals (pharmacovigilance).24

Type C AEs are associated with chronic long-term toxicity; they are insidious and common (1–10 %) but develop slowly. They are related to cumulative drug dose and are mostly reversible. These events are mainly associated with older AEDs and include unwanted cosmetic effects including hirsutism, alopecia, changes of hair structure, gingival hyperplasia, facial changes (symptoms reported with VPA, CBZ, PHT, PB and GBP). Other effects include weight gain leading to obesity (≤50 % with VPA, ≤32 % with CBZ up to 15 % with GBP or pregabalin) and weight loss leading to anorexia (≤10–20 % with felbamate and TPM).24,52–54 In addition, metabolic changes can occur; these include hyperinsulinism leading to insulin resistance and non-alcoholic steatohepatitis and polycystic ovary syndrome.55–59

Epilepsy is associated with sexual dysfunction in up to 30 % of women and 50 % of men.60 This manifests as loss of libido, erectile dysfunction and anorgasmia. The aetiology of these effects is multifactorial, but they are related to potent enzyme-inducing AEDs. The disease is also associated with osteoporosis, osteopenia and reduced bone density, which are also multifactorial in origin but linked with enzyme-inducing and non-enzyme inducing AEDs. In addition, hypothyreosis has been reported with CBZ and OXC.61,62 Patients receiving long-term CBZ, PHT or VPA have also been shown to have altered vascular risk markers (e.g. common carotid artery intima-media thickness) that may accelerate the atherosclerotic process, and this is significantly associated with the duration of AED monotherapy.63 To limit type C AEs, therefore, it is necessary to avoid long-term therapy, systematically screen patients, provide symptomatic or replacement treatment (e.g. calcium, vitamin D, folic acid) and discontinue AED if required.

Type D AEs are teratogenesis and carcinogenesis; they are uncommon (0.1–1 %) and are delayed, dose-dependent and irreversible. These can manifest as birth defects, neurodevelopmental delay, pseudolymphoma and brain tumours. Teratogenic effects are associated with prenatal exposure to AEDs, especially in the first trimester when there is a 2–3-fold increase in the risk of major congenital malformations.64 Polytherapy, high-dose treatment with VPA or PB or a family history also increases the risk of teratogenicity.64,65 Teratogenicity is mostly associated with older AEDs, but more data are needed to fully evaluate newer drugs for this risk. Type E AEs are AED interactions,66 but these were not discussed during the symposium.

An additional risk in epilepsy is suicidality, which is largely a consequence of the disease itself. This risk has not been linked with any particular drug, and there is little firm evidence to support such an association. Drugs associated with negative psychotropic effects, however, should be avoided in patients with a history of suicidal tendency.

In summary, AEDs are a complex heterogeneous set of drugs with various CNS and systemic effects. Idiosyncratic effects of AEDs are not predictable, so careful clinical observation and judgement is required. The newer AEDs have been subjected to better pre-clinical and clinical testing than the older drugs, but unexpected AEs may still arise. It is preferable to avoid strong enzyme inducing AEDs and use the newer AEDs, which are not strong inducers. There is a complex interaction between epilepsies, depression and other psychiatric comorbidities, but the risks are becoming more fully understood. Overall, ‘the devil we know’ is not better in treating epilepsy, but systematic screening for AEs and readiness to switch therapies vital to maintain treatment efficacy and QoL.

Voting Results
In post-presentation voting, most attendees (64 %) indicated that the safety profile would be the main reason for choosing a newer AED (Figure 5), but the proportions who thought AEDs have similar or dissimilar efficacy were comparable (29 % versus 33 %). In addition, most thought their choice of AED would now be an evidence-based guideline rather than a clinical experience-based guideline (58 % versus 37 %). The majority of the attendees (69 %) would now routinely screen patients who were receiving potent enzyme inducers (CBZ, PHT, PB) for lipid changes, osteoporosis or sexual dysfunction. The majority (54 %) indicated that efficacy would be the main factor in choosing an older AED.

Discussion and Conclusions
The relative efficacy evaluation of the wide range of AEDs now available has been hampered by regulatory trial designs showing only non-inferiority in the case of monotherapies and comparing only against placebo in the case of polytherapies. There is a lack of direct head-to-head studies to aid treatment choice. Meta-analyses, non-interventional and retrospective studies indicate some variation in seizure control and responder rates of different AEDs, but data ranges overlap, making identification of the most effective treatments impossible. In order to simplify treatment choice for the physician, more comparative trials are required, together with greater experience of newer AEDs in real-world use.

Whilst comparative efficacy of AEDs may be difficult to assess, significant differences between treatments exist in terms of safety and tolerability. AEs are a considerable burden in epilepsy therapy and the main cause of treatment failure, so choosing an appropriate drug or combination is critical. Some AEs are idiosyncratic, and a great benefit of the wide range of available AEDs is that treatments can be specifically tailored to the individual, minimising AEs. Validated tools can capture AEs each time patients visit a clinic, helping identify problems the patients may not mention but do affect their QoL. In elderly and other vulnerable patients, it is essential to avoid tolerability problems and choose AEDs such as LTG, LEV or ZNS, if the patient is healthy, but the physician must be ready to adapt the regimen in the case of hepatic or renal problems. Treatment decisions must be based on the individual and the evidence that supports it.

In AED polytherapy, conventional wisdom could suggest that AEDs with differing modes of action should be combined to increase efficacy and avoid increasing the risk of certain AEs. However, the efficacy showed by the combination of CBZ and ESL, which are of the same class, suggests that this belief may be incorrect.13,21 The modes of action of AEDs may be more complex than is currently appreciated, enabling similar classes of drug to work additively. The demonstration that seizure control and responder rates decline with increasing treatment number is disturbing and indicates many patients will become increasingly difficult to treat.17 The in vitro experimental findings for ESL are therefore encouraging and indicate that this drug may be effective in cases that are refractory to other treatments.

Evidence suggests that physicians should not adopt the ‘better the devil we know’ policy and continue to use the same AEDs out of habit, cost limitations or lack of experience. Alternative treatments can offer better safety and tolerability and improve patient QoL. Physicians should monitor safety carefully and be willing to change and tailor therapies to patients’ needs. The AEDs are not all the same, whilst it is difficult to show superiority of any one in terms of efficacy, it is vital to consider other drugs, especially in cases of treatment failure or in patients who have been exposed to multiple previous therapies. As newer AEDs are increasingly accepted and become more widely available, they are likely to increase choice and reduce the serious disease and treatment burdens associated with epilepsy.

Article Information:

Mar Carreño has acted as a paid consultant to UCB, Eisai, Bial, Glaxo, Medtronics, Shire and Cyberonics. She has received research funding from UCB and Eisai and has received speaker’s honoraria from GSK, Eisai, Bial, UCB, Cyberonics and Shire. Eugen Trinka has acted as a paid consultant to UCB, Eisai, Bial, Medtronics, EVER Neuro Pharma, Biogen-Idec, Takeda and Sunovion. He, or his institution, has received research funding from GSK, Biogen-Idec, Eisai, Novartis, Red Bull, Bayer, and UCB. He has received speaker’s honoraria from GSK, Böhringer Ingelheim, Eisai, Bial, UCB, Cyberonics, and Sanofi-Aventis and is CEO of Neuroconsult GmbH. Martin Holtkamp has received speaker honoraria and/or consultancy fees from Cyberonics, Desitin, Eisai, GlaxoSmithKline, Janssen-Cilag, UCB and ViroPharma.


Mar Carreño, Head, Epilepsy Unit, Department of Neurology, Hospital Clínic, Barcelona, Spain. E:


The publication of this article was supported by Eisai and Bial. The views and opinions expressed are those of the authors and not necessarily those of Eisai and Bial. All the speakers received an honorarium fee to talk at the symposium.


This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.
An erratum to this article can be found below.


Editorial assistance was provided by James Gilbart at Touch Medical Media and funded by Eisai and Bial. This article reports the proceedings
of a sponsored satellite symposium and as such has not been subject to the journal’s usual peer-review process.




1. Elger CE, Schmidt D, Modern management of epilepsy: a practical approach, Epilepsy Behav, 2008;12:501–39.
2. Chowdhury D, New drugs for the treatment of epilepsy: a practical approach, J Assoc Physicians India, 2013;61:19–39.
3. Costa J, Fareleira F, Ascencao R, et al., Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis, Epilepsia, 2011;52:1280–91.
4. French JA, White HS, Klitgaard H, et al., Development of new treatment approaches for epilepsy: unmet needs and opportunities, Epilepsia, 2013;54(Suppl. 4):3–12.
5. Trinka E, Ideal characteristics of an antiepileptic drug: how do these impact treatment decisions for individual patients? Acta Neurol Scand Suppl, 2012;194:10–8.
6. Brigo F, New anti-epileptic drugs: overcoming the limits of randomised controlled trials, Int J Evid Based Healthc, 2011;9:440–3.
7. Laxer KD, Trinka E, Hirsch LJ, et al., The consequences of refractory epilepsy and its treatment, Epilepsy Behav, 2014;37:59–70.
8. Gilliam F, What we don’t learn from clinical trials in epilepsy, Epilepsia, 2003;44(Suppl. 7):51–4.
9. Gilliam FG, Limitations of monotherapy trials in epilepsy, Neurology, 2003;60:S26–30.
10. King MA, Newton MR, Jackson GD, et al., Epileptology of the first-seizure presentation: a clinical, electroencephalographic, and magnetic resonance imaging study of 300 consecutive patients, Lancet, 1998;352:1007–11.
11. Baulac M, Brodie MJ, Patten A, et al., Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial, Lancet Neurol, 2012;11: 579–88.
12. Marson AG, Al-Kharusi AM, Alwaidh M, et al., The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial, Lancet, 2007;369:1000–15.
13. Elger C, Halasz P, Maia J, et al., Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, doubleblind, placebo-controlled, parallel-group phase III study, Epilepsia, 2009;50:454–63.
14. French JA, Abou-Khalil BW, Leroy RF, et al., Randomized,double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy, Neurology, 2011;76: 1555–63.
15. Krauss GL, Serratosa JM, Villanueva V, et al., Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures, Neurology, 2012;78:1408–15.
16. Bodalia PN, Grosso AM, Sofat R, et al., Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials, Br J Clin Pharmacol, 2013;76:649–67.
17. Schiller Y, Najjar Y, Quantifying the response to antiepileptic drugs: effect of past treatment history, Neurology, 2008;70:54–65.
18. Villanueva V, Garces M, Lopez-Gomariz E, et al., Early add-on lacosamide in a real-life setting: results of the REALLY study, Clin Drug Investig, 2015;35:121–31.
19. Holtkamp M, McMurray R, Sousa R, et al., Eslicarbazepine acetate as add-on treatment to antiepileptic monotherapy in adults with partial-onset seizures: real-world data from the EPOS study, Eur J Neurol, 2015;22(Suppl. 1):21–117.
20. Lawthom C, McMurray R, Sousa R, et al., Effectiveness of eslicarbazepine acetate as add-on treatment to antiepileptic mo-notherapy in adults with partial-onset sei-zures (EPOS study): analysis by baseline antiepileptic drugC. Eur J Neurol, 2015;22(Suppl. 1):120–483.
21. Doeser A, Dickhof G, Reitze M, et al., Targeting pharmacoresistant epilepsy and epileptogenesis with a dualpurpose antiepileptic drug, Brain, 2015;138:371–87.
22. Hoppe C, Elger CE, Depression in epilepsy: a critical review from a clinical perspective, Nat Rev Neurol, 2011;7:462–72.
23. Halasz P, Cramer JA, Hodoba D, et al., Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year openlabel extension study in partial-onset seizures in adults with epilepsy, Epilepsia, 2010;51:1963–9.
24. Perucca P, Gilliam FG, Adverse effects of antiepileptic drugs, Lancet Neurol, 2012;11:792–802.
25. Aronson JK, Drug therapy. In: Haslett C, Chilvers ER, Boon NA, et al. (eds.), Davidson’s Principles and Practice of Medicine, 19th ed, Edinburgh: Elsevier Science, 2002;147.
26. Nunes T, Rocha JF, Falcao A, et al., Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers, Epilepsia, 2013;54:108–16.
27. Ficker DM, Privitera M, Krauss G, et al., Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine, Neurology, 2005;65:593–5.
28. Krauss G, Biton V, Harvey J, et al., Adverse event profile of eslicarbazepine acetate during dose titration Phase III controlled studies of patients with refractory partial-onset seizures (Abst. 3.208), 67th Annual Meeting of the American Epilepsy Society Washington, DC, USA, 2013. Available at: abstracts/view/1749565#sthash.BXyJRzQk.dpuf.
29. Brunbech L, Sabers A, Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents, Drugs, 2002;62: 593–604.
30. Meador KJ, Cognitive and memory effects of the new antiepileptic drugs, Epilepsy Res, 2006;68:63–7.
31. Meador KJ, Effect of adjunctive perampanel on cognition in adolescents with inadequately controlled partial-onset seizures P4.344 Annual Meeting of the American Academy of Neurology, Philadelphia, USA, 2014. Available at: https:// Documents/7.Conferences/1.CONFERENCES/1.Annual_ Meeting/14AM_Extra_Tues.pdf (accessed 23 July 2015).
32. Ortinski P, Meador KJ, Neuronal mechanisms of conscious awareness, Arch Neurol, 2004;61:1017–20.
33. Sake JK, Hebert D, Isojarvi J, et al., A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs, CNS Drugs, 2010;24:1055–68.
34. Gil-Nagel A, Trinka E, Chaves J, et al., A post-hoc exploratory analysis of the effect of eslicarbazepine acetate as adjunctive treatment in adult patients with partial onset seizures refractory to carbamazepine, Epilepsy Curr, 2013;13(Suppl. 1):421–2.
35. Boylan LS, Flint LA, Labovitz DL, et al., Depression but not seizure frequency predicts quality of life in treatmentresistant epilepsy, Neurology, 2004;62:258–61.
36. Gilliam F, Optimizing health outcomes in active epilepsy, Neurology, 2002;58:S9–20.
37. Gilliam FG, Fessler AJ, Baker G, et al., Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial, Neurology, 2004;62:23–7.
38. Chadwick D, Shaw MD, Foy P, et al., Serum anticonvulsant concentrations and the risk of drug induced skin eruptions, J Neurol Neurosurg Psychiatry, 1984;47:642–4.
39. Franciotta D, Kwan P, Perucca E, Genetic basis for idiosyncratic reactions to antiepileptic drugs, Curr Opin Neurol, 2009;22:144–9.
40. Wong IC, Mawer GE, Sander JW, et al., A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy, Epilepsia, 2001;42:1354–8.
41. Glasziou P, Vandenbroucke JP, Chalmers I, Assessing the quality of research, BMJ, 2004;328:39–41.
42. Pirmohamed M, Anticipating, investigating and managing the adverse effects of drugs, Clin Med, 2005;5:23–6.
43. Vandenbroucke JP, Benefits and harms of drug treatments, BMJ, 2004;329:2–3.
44. Buck ML, Goodkin HP, Use of lacosamide in children with refractory epilepsy, J Pediatr Pharmacol Ther, 2012;17:211–9.
45. Harr T, French LE, Toxic epidermal necrolysis and Stevens- Johnson syndrome, Orphanet J Rare Dis, 2010;5:39.
46. Messenheimer JA, Rash in adult and pediatric patients treated with lamotrigine, Can J Neurol Sci, 1998;25:S14–8.
47. Chen P, Lin JJ, Lu CS, et al., Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan, N Engl J Med, 2011;364:1126–33.
48. McCormack M, Alfirevic A, Bourgeois S, et al., HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans,N Engl J Med, 2011;364:1134–43.
49. Blackburn SC, Oliart AD, Garcia Rodriguez LA, et al., Antiepileptics and blood dyscrasias: a cohort study,Pharmacotherapy, 1998;18:1277–83.
50. Kalviainen R, Nousiainen I, Visual field defects with vigabatrin: epidemiology and therapeutic implications, CNS Drugs, 2001;15:217–30.
51. Ho JD, Keller JJ, Tsai CY, et al., Topiramate use and the risk of glaucoma development: a population-based follow-up study, Am J Ophthalmol, 2013;155:336–41 e1.
52. Aneja S, Sharma S, Newer anti-epileptic drugs, Indian Pediatr, 2013;50:1033–40.
53. Beghi E, Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines, Lancet Neurol, 2004;3:618–21.
54. Kennedy GM, Lhatoo SD, CNS adverse events associated with antiepileptic drugs, CNS Drugs, 2008;22:739–60.
55. El-Khatib F, Rauchenzauner M, Lechleitner M, et al., Valproate, weight gain and carbohydrate craving: a gender study, Seizure, 2007;16:226–32.
56. Luef G, Abraham I, Hoppichler F, et al., Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy, Metabolism, 2002;51:1274–8.
57. Luef G, Abraham I, Trinka E, et al., Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy, Neurology, 2001;57:565–6.
58. Luef G, Rauchenzauner M, Waldmann M, et al., Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment, Epilepsy Res, 2009;86:42–7.
59. Luef GJ, Waldmann M, Sturm W, et al., Valproate therapy and nonalcoholic fatty liver disease, Ann Neurol, 2004;55:729–32.
60. Luef G, Madersbacher H, Sexual dysfunction in patients with epilepsy, Handb Clin Neurol, 2015;130:383–94.
61. Benedetti MS, Whomsley R, Baltes E, et al., Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction, Eur J Clin Pharmacol, 2005;61:863–72.
62. Isojarvi JI, Turkka J, Pakarinen AJ, et al., Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy, Epilepsia, 2001;42:930–4.
63. Chuang YC, Chuang HY, Lin TK, et al., Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis, Epilepsia, 2012;53:120–8.
64. Tomson T, Battino D, The management of epilepsy in pregnancy. In: Shorvon S, Pedley TA (eds.), The Blue Books of Neurology: The Epilepsies 3, Philadelphia, PA: Saunders Elsevier, 2009;241–64.
65. Tomson T, Battino D, Bonizzoni E, et al., Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry, Lancet Neurol, 2011;10:609–17.
66. Johannessen SI, Landmark CJ, Antiepileptic drug interactions – principles and clinical implications, Curr Neuropharmacol, 2010;8:254–67.

Further Resources

Share this Article
Related Content In Epilepsy
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72